Climb Bio Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Climb Bio.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	27.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Climb Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGM:CLYM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	N/A	-64	0	0	N/A
3/31/2024	N/A	-15	-7	-7	N/A
12/31/2023	N/A	-35	-21	-21	N/A
9/30/2023	N/A	-39	-28	-28	N/A
6/30/2023	N/A	-45	-36	-36	N/A
3/31/2023	N/A	-54	-42	-42	N/A
12/31/2022	N/A	-45	-37	-37	N/A
9/30/2022	N/A	-48	-37	-37	N/A
6/30/2022	N/A	-49	-46	-46	N/A
3/31/2022	N/A	-46	-40	-40	N/A
12/31/2021	N/A	-52	-36	-36	N/A
9/30/2021	N/A	-57	-34	-34	N/A
6/30/2021	N/A	-49	-23	-23	N/A
3/31/2021	N/A	-40	-19	-19	N/A
12/31/2020	N/A	-23	-14	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CLYM's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if CLYM's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CLYM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CLYM's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CLYM's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CLYM's Return on Equity is forecast to be high in 3 years time

Climb Bio Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$6.00

Recent updates

Climb Bio, Inc. Announces Board Changes

Climb Bio, Inc. Present Additional Data from the Completed Pmn Trial and Share Clinical Data from A Single Patient with Minimal Change Disease (Mcd) Treated with Budoprutug

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. (NasdaqGM:ELYM) completed the acquisition of Tenet Medicines, Inc. from RA Capital Management, L.P. and others.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics, Inc. announced that it has received $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

New major risk - Share price stability

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

New minor risk - Shareholder dilution

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Price target decreased to US$6.00

Eliem Therapeutics, Inc. Provides Update on Pipeline Progress

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics, Inc. Provides ETX-810 Program Update

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of ETX-810 in Patients with Lumbosacral Radicular Pain

Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from Russell 2500 Value Index

Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-810 for the Treatment of Diabetic Peripheral Neuropathic Pain and Provided an Update on the Status of the ETX-155 Clinical Program in Epilepsy and Depression

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies